|
注册号: Registration number: |
ChiCTR2000030171 |
|
最近更新日期: Date of Last Refreshed on: |
2020-02-24 19:14:27 |
|
注册时间: Date of Registration: |
2020-02-24 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
多中心、随机、双盲、标准治疗基础上的安慰剂平行对照评价注射用重组人纽兰格林对慢性收缩性心力衰竭患者死亡率影响的III期临床试验。 |
|
Public title: |
A Multi-Center, Randomized, Double-Blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy. |
|
注册题目简写: |
评价重组人纽兰格林对慢性心力衰竭患者死亡率影响的临床试验。 |
|
English Acronym: |
Mortality Study of Recombinant Human Neuregulin-1β to Treat Chronic Heart Failure (CHF) Patients. |
|
研究课题的正式科学名称: |
多中心、随机、双盲、标准治疗基础上的安慰剂平行对照评价注射用重组人纽兰格林对慢性收缩性心力衰竭患者死亡率影响的III期临床试验。 |
|
Scientific title: |
A Multi-Center, Randomized, Double-Blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy. |
|
研究课题代号(代码): Study subject ID: |
ZS-01-306 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
秦晓彦 |
研究负责人: |
高润霖 |
|
Applicant: |
Xiaoyan Qin |
Study leader: |
Runlin Gao |
|
申请注册联系人电话: Applicant telephone: |
+86 18321257739 |
研究负责人电话:
Study leader's |
+86 010-68331622 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
qinxiaoyan@zensun.com |
研究负责人电子邮件: Study leader's E-mail: |
gaorunlin@citmd.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区居里路68号 |
研究负责人通讯地址: |
北京市西城区北礼士路167号 |
|
Applicant address: |
68 Juli Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, China |
Study leader's address: |
167 North Lishi Road, Xicheng District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海泽生科技开发股份有限公司 |
||
|
Applicant's institution: |
Zensun (Shanghai) Sci. & Tech. Co., Ltd |
||
|
研究负责人所在单位: |
阜外医院 |
||
|
Affiliation of the Leader: |
Fuwai Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2017-970 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
阜外医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Fuwai Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2018-12-25 00:00:00 | ||
|
伦理委员会联系人: |
赵志晶 |
||
|
Contact Name of the ethic committee: |
Zhijing Zhao |
||
|
伦理委员会联系地址: |
北京市西城区北礼士路167号 |
||
|
Contact Address of the ethic committee: |
167 North Lishi Road, Xicheng District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中国医学科学院阜外医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fuwai Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区北礼士路167号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
167 North Lishi Road, Xicheng District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海泽生科技开发股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zensun (Shanghai) Sci. & Tech. Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
慢性心力衰竭 |
||||||||||||||||||||||
|
Target disease: |
Chronic Heart Failur |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
III期临床试验 | ||||||||||||||||||||||
|
Study phase: |
3 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估注射用重组人纽兰格林对600 pg/ml ≤ NT-proBNP ≤ 1700 pg/ml,纽约心功能分级II/III级慢性收缩性心力衰竭患者死亡率的影响,确定其疗效和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600pg/ml and 1700 pg/mL and NYHA class II to III. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 新近诊断慢性心衰患者,或接受心衰基础治疗药物不满三个月者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. New chronic heart failure patients, or patients receiving standard therapy |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2018-02-27 00:00:00至 To 2023-02-28 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2018-02-27 00:00:00 至 To 2023-02-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
第四军医大学卫生统计学教研室采用中心分层的区组随机化方法由中央随机化系统执行随机。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The Department of Health Statistics of the Fourth Military Medical University uses a central layered block randomization method to perform randomization by a central randomization system. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double blind |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan, http://www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
eCRF 和 EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
eCRF and EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |